<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63663">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01777737</url>
  </required_header>
  <id_info>
    <org_study_id>TriSulfa-FPI-1</org_study_id>
    <nct_id>NCT01777737</nct_id>
  </id_info>
  <brief_title>Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole</brief_title>
  <acronym>TriSulfa-FPI</acronym>
  <official_title>Pilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Junta de Andalucia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First study to test the validity of the treatment of idiopathic pulmonary fibrosis, which
      causes inflammation and fibrosis (scarring) of the lung tissue, with cotrimoxazole.

      Cotrimoxazole may improve the clinical course of the disease through eradication of
      Pneumocystis jiroveci colonization and other mechanisms as inhibiting the activation of
      alveolar macrophages and producing alterations in the surfactant system which favours the
      persistent activation of the inflammatory response and the development of pulmonary
      fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that is clinically manifested
      by the appearance of effort dyspnea and impaired lung function.

      The natural history of the disease is poorly understood and there is no clear consensus as
      to the most appropriate markers for predicting patient outcome.

      This pilot controlled trial aims to test the efficacy and safety of cotrimoxazole in the
      treatment of IPF. This novel therapeutic strategy, with very encouraging preliminary data is
      based on its pathophysiological basis, primarily related to the elimination of Pneumocystis
      colonization. That elimination, could serve as a potent weapon for reducing morbidity and
      mortality and the cost associated with this devastating disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluate the efficacy of oral cotrimoxazole versus placebo in idiopathic pulmonary fibrosis (IPF).</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Decline of the FVC ≥ 5% at 24 weeks and / or hospitalization for respiratory causes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety of oral cotrimoxazole versus placebo in IPF.</measure>
    <time_frame>At 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to progression
Any cause of hospitalization
Overall mortality
Incidence and severity of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of cotrimoxazole on the natural history of Pneumocystis colonization in patients with IPF.</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Molecular diagnosis of colonization by Pneumocystis jiroveci.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify the effects of cotrimoxazole systemic level of inflammatory activity in patients with IPF.</measure>
    <time_frame>At 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Acute exacerbation of IPF
Scales of dyspnea
Reduction &gt; 50% in the values of different proinflammatory cytokines
Reduction &gt; 50% in the values of surfactant proteins.
Reduction &gt; 50% in the values of chemokine CCL-18.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cotrimoxazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sulfamethoxazole 400 mg. + trimethoprim 80 mg. weight-adjusted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical capsules to cotrimoxazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cotrimoxazole</intervention_name>
    <description>24 weeks of treatment</description>
    <arm_group_label>Cotrimoxazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical capsules to cotrimoxazole</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo with identical physical appearance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient, regardless of gender, aged 18 to 80 years.

          -  Well-established diagnostic criteria of the Idiopathic Pulmonary Fibrosis (IPF) as
             ATA/ERS/JRS/ALAT 2011.

          -  Ability to obtain a sample of sputum or oropharyngeal washing.

          -  Forced Vital Capacity (FVC) above 50% from the theoretical value expected.

          -  Patient compliance or legal guardian to participate in this study by signing the
             informed consent.

        Exclusion Criteria:

          -  Allergy / hypersensitivity or known gastrointestinal intolerance to cotrimoxazole.

          -  Use of immunosuppressants or corticosteroids in the previous 90 days at baseline.

          -  Exacerbation of IPF and / or pneumonia in the 90 days prior to baseline.

          -  Presence of autoimmune diseases or asthma.

          -  Patients with other significant diseases other than IPF. It is considered significant
             disease any disease or condition that, in the investigator's opinion, may jeopardize
             the patient's health participating in the study or influence the results of the study
             or the patient's ability to participate in the study.

          -  Pregnant or lactating or of childbearing potential not using medically approved
             contraceptive methods at least three months before or during trial.

          -  Participation in another trial with an investigational drug within 30 days or six
             half-lives (the larger of the two) above the baseline.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francisco J. Medrano Ortega, PhD</last_name>
    <email>medrano@cica.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernando Pérez Martínez, PhD</last_name>
    <phone>955013414</phone>
    <email>fernando.perez.exts@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío/ Instituto de Biomedicina de Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francisco J Medrano Ortega, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>January 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <keyword>Trimethoprim-sulfamethoxazole</keyword>
  <keyword>Pneumocystis jiroveci</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim-Sulfamethoxazole Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
